Start › Szpiczak mnogi › New Jersey
Badania kliniczne dla Szpiczak mnogi w stanie New Jersey
38 badań dla Szpiczak mnogi szuka uczestników w ośrodkach w stanie New Jersey.
Miasta w stanie New Jersey
Oficjalny tekst badania (angielski)
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
RekrutacjaFaza 2
Wiek 60 i więcej · Obie płcie · Zaktualizowano 1 paź 2026 · NCT06679829A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Local Institution - 0363, Ridgewood
RekrutacjaFaza 3
Wiek 18 i więcej · Obie płcie · Zaktualizowano 30 wrz 2026 · NCT05519085A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Hackensack University Medical Center, Hackensack
RekrutacjaFaza 1/2
Wiek 18 i więcej · Obie płcie · Zaktualizowano 28 wrz 2026 · NCT04973605A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Astera Cancer Care, East Brunswick
RekrutacjaFaza 3
Wiek 18 i więcej · Obie płcie · Zaktualizowano 25 wrz 2026 · NCT07518186A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Astera Cancer Care, East Brunswick
RekrutacjaFaza 3
Wiek 18 i więcej · Obie płcie · Zaktualizowano 25 wrz 2026 · NCT05552222A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- MSK Basking Ridge, Basking Ridge
- MSK Monmouth, Middletown
- MSK Bergen, Montvale
RekrutacjaFaza 3
Wiek 18 i więcej · Obie płcie · Zaktualizowano 25 wrz 2026 · NCT05623020A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Hackensack University Medical Center, Hackensack
- Rutgers Cancer Institute of New Jersey, New Brunswick
RekrutacjaFaza 4
Wiek 18 i więcej · Obie płcie · Zaktualizowano 25 wrz 2026 · NCT05201781Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
- Hackensack Meridian Health - John Theurer Cancer Center, Hackensack
RekrutacjaFaza 1
Wiek 18 i więcej · Obie płcie · Zaktualizowano 21 wrz 2026 · NCT03909412A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
- John Theurer Cancer Center, Hackensack
RekrutacjaFaza 2
Wiek 18 i więcej · Obie płcie · Zaktualizowano 21 wrz 2026 · NCT04661137Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Hackensack Meridian Health, Hackensack
- Carol G Simon Cancer Center, Morristown
RekrutacjaFaza 3
Wiek 18 i więcej · Obie płcie · Zaktualizowano 21 wrz 2026 · NCT07648264Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale
RekrutacjaFaza 2
Wiek 18 i więcej · Obie płcie · Zaktualizowano 15 wrz 2026 · NCT06976476Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Rutgers Cancer Institute of New Jersey, New Brunswick
RekrutacjaFaza 2
Wiek 18 i więcej · Obie płcie · Zaktualizowano 14 wrz 2026 · NCT06297226A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- Hackensack University Medical Center, Hackensack
RekrutacjaFaza 1/2
Wiek 18 i więcej · Obie płcie · Zaktualizowano 2 wrz 2026 · NCT06988488A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack
RekrutacjaFaza 1
Wiek 18 i więcej · Obie płcie · Zaktualizowano 28 sie 2026 · NCT07075185A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Research Site, Hackensack
RekrutacjaFaza 1/2
Wiek 18 i więcej · Obie płcie · Zaktualizowano 27 sie 2026 · NCT07681596MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Atlantic Health System Morristown Medical Center, Morristown
RekrutacjaFaza 3
Wiek 18 i więcej · Obie płcie · Zaktualizowano 24 sie 2026 · NCT06152575A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- MSK Basking Ridge, Basking Ridge
- MSK Monmouth, Middletown
- MSK Bergen, Montvale
RekrutacjaFaza 3
Wiek 18 i więcej · Obie płcie · Zaktualizowano 24 sie 2026 · NCT05020236Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Jefferson Cherry Hill Hospital, Cherry Hill
- Sidney Kimmel Cancer Center Washington Township, Sewell
RekrutacjaFaza 3
Wiek 18 i więcej · Obie płcie · Zaktualizowano 19 sie 2026 · NCT04566328A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Hackensack University Medical Center, Hackensack
RekrutacjaFaza 1
Wiek 18 i więcej · Obie płcie · Zaktualizowano 18 sie 2026 · NCT05651932A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
RekrutacjaFaza 1
Wiek 18 i więcej · Obie płcie · Zaktualizowano 17 sie 2026 · NCT07105059Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, East Brunswick
RekrutacjaFaza 3
Wiek 18 i więcej · Obie płcie · Zaktualizowano 14 sie 2026 · NCT07764978A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Consent only), Middletown
- Memorial Sloan Kettering Bergen (Consent Only), Montvale
RekrutacjaBadanie obserwacyjne
Wiek 18 i więcej · Obie płcie · Zaktualizowano 6 sie 2026 · NCT07249528Mosaic Trial for Stem Cell Transplant Recipients
- Hackensack Meridian Health, Nutley
Rekrutacja
Wiek 18 i więcej · Obie płcie · Zaktualizowano 3 sie 2026 · NCT06960993A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
RekrutacjaFaza 1/2
Wiek 18 i więcej · Obie płcie · Zaktualizowano 28 lip 2026 · NCT07099391A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
RekrutacjaFaza 1
Wiek 18 i więcej · Obie płcie · Zaktualizowano 16 lip 2026 · NCT06121843A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
RekrutacjaFaza 2
Wiek 18 i więcej · Obie płcie · Zaktualizowano 6 lip 2026 · NCT06083922A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale
RekrutacjaFaza 2
Wiek 18 i więcej · Obie płcie · Zaktualizowano 16 cze 2026 · NCT07454382Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization
- Rutgers Cancer Institute of New Jersey, New Brunswick
- RWJBarnabas Health - Robert Wood Johnson University Hospital, New Brunswick, New Brunswick
RekrutacjaWczesna faza 1
Wiek 18 i więcej · Obie płcie · Zaktualizowano 29 maj 2026 · NCT04211259A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
- Rutgers Cancer Institute of New Jersey, New Brunswick
RekrutacjaFaza 1/2
Wiek 18 i więcej · Obie płcie · Zaktualizowano 13 maj 2026 · NCT05828511Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Rutgers Cancer Institute of New Jersey /ID# 266833, New Brunswick
RekrutacjaFaza 1
Wiek 18 i więcej · Obie płcie · Zaktualizowano 12 maj 2026 · NCT06896916A Dietary Study for People With Multiple Myeloma
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
Rekrutacja
Wiek 18 i więcej · Obie płcie · Zaktualizowano 5 maj 2026 · NCT07226609A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Hackensack
RekrutacjaFaza 3
Wiek 18 i więcej · Obie płcie · Zaktualizowano 22 kwi 2026 · NCT06679101A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Atlantic Health, Morristown
- Rutgers Cancer Institute of New Jersey, New Brunswick
RekrutacjaFaza 1/2
Wiek 12 i więcej · Obie płcie · Zaktualizowano 24 mar 2026 · NCT04988555A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
RekrutacjaFaza 2
Wiek 18 i więcej · Obie płcie · Zaktualizowano 4 mar 2026 · NCT06066346Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Memorial Sloan Kettering Monmouth, Middletown
RekrutacjaBadanie obserwacyjneZapraszamy zdrowych ochotników
W każdym wieku · Obie płcie · Zaktualizowano 23 sty 2026 · NCT00582621A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale
Rekrutacja
Wiek 18 i więcej · Obie płcie · Zaktualizowano 13 lis 2025 · NCT06055894CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- Hackensack Meridian John Theurer Cancer Center, Hackensack
RekrutacjaFaza 1
Wiek 18 i więcej · Obie płcie · Zaktualizowano 25 wrz 2025 · NCT05722418A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
- John Theurer Cancer Center at Hackensack UMC, Hackensack
RekrutacjaFaza 1/2
Wiek 18 i więcej · Obie płcie · Zaktualizowano 5 wrz 2025 · NCT05372354Źródło: ClinicalTrials.gov, dane pobrane 3 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.